In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.
In vivo administration of interleukin-2 (IL-2)-secreting tumor cells results in complete protection against persistent infection by Theiler's murine encephalomyelitis virus (TMEV) in susceptible DBA/2 mice. The IL-2-mediated protection was found to depend on the inoculum size as well as the timing o...
Tallennettuna:
| Julkaisussa: | J Virol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology (ASM)
1997
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC191120/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8985419/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.71.1.797-799.1997 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|